GlobeNewswire Inc | Sep 2, 2021 04:34PM EDT

September 02, 2021

PRESS RELEASE

Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference

Mont-Saint-Guibert, Belgium September 2, 2021, 10:30pm CET / 4:30pm ET Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(Nyxoah or the Company), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, and Fabian Suarez, Chief Financial Officer, will participate at the Baird 2021 Global Healthcare Conference on Tuesday, September 14, 2021, with a virtual presentation at 3:05 pm CET / 9:05 am ET.

A live webcast and replay of this event will be available on the Companys investors relations website at https://investors.nyxoah.com/

About NyxoahNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoahs lead solution is the Genio system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the worlds most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in 2019. The Company has completed the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion and is currently conducting the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio system.

Contacts:NyxoahFabian Suarez, Chief Financial Officercorporate@nyxoah.com+32 (0)10 22 24 55

Gilmartin GroupVivian CervantesIR@nyxoah.com

Attachment

-- ENGLISH - NYXH Announces Baird HC 2021 Conf - FINAL